Mark Connell
Mark Connell is Co-Founder & President of SLBST Pharma, which is developing a non-hormonal therapy for endometriosis. Our lead candidate is a reformulated immunomodulator, which has a green light from the FDA for a Phase 2b clinical trial. Mark entered the pharmaceutical world 30 years ago when he helped to reestablish the operations of a pharmaceutical manufacturer in Vietnam.